ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for ...

Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high single-digit organic growth in ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Bio-Techne Corporation (TECH) stock climbs as its Q2 FY25 results exceed Wall Street estimates amid recovery in the biopharma end market. Read more here.

This compares to the stock's 16.8% gain over the past four weeks. The company provides advanced bioprocessing technologies and solutions that are used by large biopharmaceutical companies and ...

META_DESC_INVESTMENT_IDEA ...